100
Participants
Start Date
November 5, 2018
Primary Completion Date
October 8, 2020
Study Completion Date
September 1, 2030
Paclitaxel
"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
Trastuzumab
Trastuzumab works by targeting the HER2/neu receptor on cancer cells
Pertuzumab
Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
DF/BWCC at Milford Regional Medical Center, Milford
DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth
Collaborators (1)
Susan G. Komen Breast Cancer Foundation
OTHER
Breast Cancer Research Foundation
OTHER
Terri Brodeur Breast Cancer Foundation
UNKNOWN
Dana-Farber Cancer Institute
OTHER